Clearside Biomedical (NASDAQ:CLSD) Stock Rating Reaffirmed by Needham & Company LLC

Clearside Biomedical (NASDAQ:CLSD – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at Needham & Company LLC in a note issued to investors on Thursday, Benzinga reports. They presently have a $4.00 price target on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 222.58% from […]

Related Keywords

United States ,America ,Bradfordt Whitmore ,Victor Chong ,Clearside Biomedical Inc ,Vanguard Group Inc ,America Corp ,Securities Exchange Commission ,Blackrock Inc ,Renaissance Technologies ,Needham Company ,Clearside Biomedical ,Get Free Report ,Biomedical Stock Down ,Exchange Commission ,Ngai Hang Victor Chong ,Street Corp ,Clearside Biomedical Daily ,